BNP Paribas Financial Markets Has $179,000 Stock Holdings in Cara Therapeutics, Inc. (NASDAQ:CARA)

BNP Paribas Financial Markets decreased its position in Cara Therapeutics, Inc. (NASDAQ:CARA) by 45.9% during the 3rd quarter, Holdings Channel reports. The firm owned 582,536 shares of the biopharmaceutical company’s stock after selling 494,271 shares during the quarter. BNP Paribas Financial Markets’ holdings in Cara Therapeutics were worth $179,000 at the end of the most recent reporting period.

Separately, Disciplined Growth Investors Inc. MN boosted its position in Cara Therapeutics by 6.6% in the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 120,660 shares in the last quarter. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Cara Therapeutics in a report on Sunday. They set a “sell” rating for the company. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the company. Based on data from MarketBeat.com, Cara Therapeutics presently has an average rating of “Hold” and a consensus price target of $2.32.

Cara Therapeutics Stock Down 3.2 %

Cara Therapeutics stock opened at $0.25 on Wednesday. The stock has a 50-day simple moving average of $0.29 and a 200 day simple moving average of $0.33. The stock has a market capitalization of $13.70 million, a price-to-earnings ratio of -0.14 and a beta of 0.64. Cara Therapeutics, Inc. has a 12-month low of $0.24 and a 12-month high of $1.17.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.